Silmitasertib | CX-4945 | Casein Kinase 2 Inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / Casein Kinase / Silmitasertib

Silmitasertib 99%+

货号：A103748 同义名： CX-4945

Silmitasertib 是一种选择性的 CK2 抑制剂，对 CK2 具有高亲和力，对 CK2α 和 CK2α' 的 IC50值均为 1 nM。Silmitasertib 具有抗肿瘤和抗炎作用，主要用于癌症和炎症相关疾病的研究。

Silmitasertib 化学结构
CAS号：1009820-21-6

Silmitasertib 3D分子结构
CAS号：1009820-21-6

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Silmitasertib 纯度/质量文件产品仅供科研

货号：A103748 标准纯度： 99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Cell,2024. Ambeed. [ A125712 ]; • Cancer Discov., 2024. Ambeed. [ A285925 ]; • JMC, 2024. Ambeed. [ A288696 ]; • JMC, 2024. Ambeed. [ A524399 , A633512 , A144280 , A174613 ]; • EJNMMI Radiopharm. Chem., 2024, 9, 61. Ambeed. [ A1257961 , A622068 ]; 更多 >

Casein Kinase 亚型比较

产品名称	CK1 ↓ ↑	CK2 ↓ ↑	其他靶点	纯度
PF-670462 2HCl	++++ CK1ε, IC50: 90 nM CK1δ, IC50: 13 nM			99%+
D4476	++ CK1 from Schizosaccharomyces pombe, IC50: 200 nM CK1δ, IC50: 300 nM			99%+
SR-3029	+++ CK1ε, IC50: 260 nM CK1δ, IC50: 44 nM			99%+
IWP-2	+++ ^M82FCK1δ, IC50: 40 nM		Wnt	99%+
LY364947	++ CK1δ, IC50: 0.22 μM			98%
TA-01	++++ CK1ε, IC50: 6.4 nM CK1δ, IC50: 6.8 nM		p38 MAPK	99%+
IC261	+ CK1, IC50: 16 μM			98%
PF-4800567	+++ casein kinase 1 delta, IC50: 711 nM casein kinase 1 epsilon, IC50: 32 nM			99%+
CK1-IN-1	++++ CK1ε, IC50: 16 nM CK1δ, IC50: 15 nM			99%+
Longdaysin	+ CKIδ, IC50: 8.8 μM CKIα, IC50: 5.6 μM			99%+
Silmitasertib		++++ CK2, IC50: 1 nM		99%+
Ellagic acid (hydrate)		+++ CK2, IC50: 0.04 μM	PKA	95+%
DMAT		+++ CK2, Ki: ~40 nM		99%+
Hematein		++ CK2, IC50: 0.55 μM		98+%
Silmitasertib sodium salt		++++ CK2α, IC50: 1 nM CK2α', IC50: 1 nM		99%+
LY294002		+++ CK2, IC50: 98 nM		99%+
A-3 HCl	+ CK1, Ki: 80 μM	++ CK2, Ki: 5.1 μM	MLCK,PKA,PKC	98+%
TBB	+ CK1, Ki: 47 μM	++ CK2, Ki: 0.4 μM		99%+
TTP 22		++ CK2, IC50: 100 nM		98%+
DRB		✔		99%+
BioE-1115		+ CK2α, IC50: 10 μM		99%+
(E/Z)-GO289		++++ CK2, IC50: 7 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Silmitasertib 生物活性

靶点	CK2 CK2, IC50:1 nM
描述	Silmitasertib (CX-4945) leads to cell-cycle arrest and selectively induces apoptosis in cancer cells compared to normal cells. This action is associated with the attenuation of PI3K/Akt signaling and the antiproliferative activity of Silmitasertib is linked to the expression levels of the CK2α catalytic subunit^[1]. When combined with PS-341, Silmitasertib prevents leukemic cells from initiating a functional unfolded protein response (UPR) to counteract PS-341-induced proteotoxic stress in the ER lumen. It also reduces the expression of the pro-survival ER chaperone BIP/Grp78^[2]. Silmitasertib induces cytotoxicity and apoptosis and exerts antiproliferative effects in hematological tumors. It achieves these effects by downregulating CK2 expression and inhibiting the activation of CK2-mediated PI3K/Akt/mTOR signaling pathways^[3].
体内研究	Administered orally at doses of 25 or 75 mg/kg, Silmitasertib is well-tolerated and shows significant antitumor activity in murine xenograft models. This efficacy is accompanied by reductions in the biomarker phospho-p21 (T145)^[1].
体外研究	Silmitasertib (CX-4945) leads to cell-cycle arrest and selectively induces apoptosis in cancer cells compared to normal cells. This action is associated with the attenuation of PI3K/Akt signaling and the antiproliferative activity of Silmitasertib is linked to the expression levels of the CK2α catalytic subunit^[1]. When combined with PS-341, Silmitasertib prevents leukemic cells from initiating a functional unfolded protein response (UPR) to counteract PS-341-induced proteotoxic stress in the ER lumen. It also reduces the expression of the pro-survival ER chaperone BIP/Grp78^[2]. Silmitasertib induces cytotoxicity and apoptosis and exerts antiproliferative effects in hematological tumors. It achieves these effects by downregulating CK2 expression and inhibiting the activation of CK2-mediated PI3K/Akt/mTOR signaling pathways^[3].
作用机制	CX-4945 acts as an ATP-competitive inhibitor of both isoforms of CK2 catalytic subunits, CK2α and CK2α’, directly blocking the phosphorylation of Akt at Serine 129 in PI3K/Akt signaling pathway.

Silmitasertib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
A431	10 μM	Function Assay	30 min	attenuates PI3K-Akt-mTOR signaling	22387988
A431	10 μM	Function Assay	4-24 h	enhances apoptosis with erlotinib	22387988
A549	3/10 μM	Function Assay	48 h	suppresses the micropillar-induced expression of p-FAK	26318800
A549	10 μM	Function Assay	12/24/48 h	inhibits TGF-β1-induced migration and invasion	24023938

Silmitasertib 动物研究

Dose

Mice: 25 mg/kg - 75 mg/kg^[2] (p.o.)

Administration

p.o.

Pharmacokinetics

Animal	Mice^[2]	Rats^[2]	Dogs^[2]
Dose	5 mg/kg (i.v.) 25 mg/kg (p.o.)	5.2 mg/kg (i.v.) 10.5 mg/kg (p.o.)	1.9 mg/kg (i.v.) 8.2 mg/kg (p.o.)
Administration	i.v. p.o.	i.v. p.o.	i.v. p.o.
F	20% (p.o.)	48% (p.o.)	51% (p.o.)
T_1/2	5 h (i.v.)	11.6 h (i.v.)	8.3 h (i.v.)
AUC	2009 ng·h/ml (p.o.)	42343 ng·h/ml (p.o.)	5646 ng·h/ml (p.o.)
CL	2.5 L/h/kg (i.v.)	0.1 L/h/kg (i.v.)	0.7 L/h/kg (i.v.)
C_max	311 ng/ml (p.o.)	7369 ng/ml (p.o.)	2178 ng/ml (p.o.)
Vss	18.1 L/kg (i.v.)	2.0 L/kg (i.v.)	8.9 L/kg (i.v.)

Silmitasertib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00891280	Advanced Solid Tumors ... 展开 >> Breast Cancer Inflammatory Breast Cancer Castleman's Disease Multiple Myeloma 收起 <<	Phase 1	Unknown	December 2011	United States, Arizona ... 展开 >> Mayo Clinic Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Office Mayo Clinic Cancer Center 507-538-7623 Principal Investigator: Donald Northfelt, MD United States, Colorado Front Range Cancer Specialists Recruiting Fort Collins, Colorado, United States, 80528 Contact: P. Zeller 970-212-7609 Principal Investigator: Robert F Marschke, MD Front Range Cancer Specialists Recruiting Loveland, Colorado, United States, 80528 Contact: Pat Zeller 970-212-7609 Principal Investigator: R. McFarland, MD United States, Texas U T M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: R. Alvarez, MD ralvarez@mdanderson.org Principal Investigator: R. Alvarez, MD 收起 <<
NCT03571438	Kidney Cancer	Not Applicable	Recruiting	September 30, 2024	France ... 展开 >> Grenoble Alps Hospital Recruiting Grenoble, France, 38043 Contact: Jean-Luc Descotes, PU-PH 收起 <<
NCT02128282	Cholangiocarcinoma	Phase 1 Phase 2	Recruiting	November 2021	United States, Arizona ... 展开 >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Mitesh Borad, M.D. United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard 720-848-0702 Amy.Szilard@ucdenver.edu Principal Investigator: Sarah (Lindsey) Davis, MD United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Kabir Mody, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Joleen Hubbard, MD United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN 214-370-1937 tammy.carmical@usoncology.com Principal Investigator: Carlos Becerra, M.D. Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN 903-579-9869 karen.poe@usoncology.com Principal Investigator: Donald A Richards, M.D. Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD 82-3010-3219 ext 3210 changhm@amc.seoul.kr Contact: Seok kyung Jeong 82-2-3010-5634 jsk0213@amc.seoul.kr Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee 82-2-3410-0955 ley0709@samsung.com Principal Investigator: Joon Oh Park, MD Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi 82-2-2072-7612 iamyou3@hanmail.net Principal Investigator: Do-Youn Oh, MD Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang 82-2-2228-8180 syhwang@yuhs.ac Principal Investigator: Sun Young Rha, MD Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu +886-4-2205-2121 peggyshiu0807@gmail.com Principal Investigator: Li-Yuan Bai, M.D. 收起 <<

Silmitasertib 参考文献

[1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.

[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.

[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.

Silmitasertib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.30mL

2.86mL

1.43mL

28.59mL

5.72mL

2.86mL

Silmitasertib 技术信息

CAS号	1009820-21-6
分子式	C₁₉H₁₂ClN₃O₂
分子量	349.771

别名	CX-4945
运输	蓝冰

存储条件

粉末 Keep in dark place,Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 35 mg/mL(100.07 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

0.1 M NaOH: 30 mg/mL(85.77 mM)，配合低频超声，并调节pH至9

动物实验配方

1% CMC Na+water 30 mg/mL suspension

细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源

A431	10 μM	Function Assay	30 min	attenuates PI3K-Akt-mTOR signaling	22387988
A431	10 μM	Function Assay	4-24 h	enhances apoptosis with erlotinib	22387988
A549	3/10 μM	Function Assay	48 h	suppresses the micropillar-induced expression of p-FAK	26318800
A549	10 μM	Function Assay	12/24/48 h	inhibits TGF-β1-induced migration and invasion	24023938
A549	3 μM	Function Assay	48 h	inhibits TGF-β1-induced activation of Smad and expression of Snail and Twist	24023938
A549	0-30 μM	Growth Inhibition Assay	72 h	IC50=4.15 μM, inhibits cell growth concentration dependently	23651443
A549	1/10 μM	Function Assay	48 h	leads to a dose-dependent decrease in Notch reporter activity	23651443
ALL-SIL	1-10 μM	Growth Inhibition Assay	48 h	IC50=5.7 μM	24253024
ALL-SIL	5 μM	Apoptosis Assay	24/48 h	induces apoptosis	24253024
ARPE-19	5/10/20 μM	Kinase Assay	24/48 h	inhibits CK2 kinase activity at a concentration of 5 μM	24686080
ARPE-19	10 μM	Growth Inhibition Assay	24-96 h	inhibits cell growth time dependently	24686080
ARPE-19	10 μM	Function Assay	4 h	causes ER-stress response over the p-eIF2α branch, but does not induce CHOP	24686080
C2C12	3 μM	Function Assay	12/24/48 h	inhibits the expression of osteoclast differentiation markers and Akt phosphorylation	24293011
Calu-1	1/5/10 μM	Growth Inhibition Assay	72 h	inhibits cell growth concentration dependently	25750308
Calu-1	10 μM	Apoptosis Assay	72 h	induces apoptosis	25750308
CEM-R	1-10 μM	Growth Inhibition Assay	48 h	IC50=4 μM	24253024
CEM-S	1-10 μM	Growth Inhibition Assay	48 h	IC50=4.6 μM	24253024
DND-41	1-10 μM	Growth Inhibition Assay	48 h	IC50=9 μM	24253024
DND-41	5 μM	Apoptosis Assay	24/48 h	induces apoptosis	24253024
H1299	1/5/10 μM	Growth Inhibition Assay	72 h	inhibits cell growth concentration dependently	25750308
H1299	10 μM	Apoptosis Assay	72 h	induces apoptosis	25750308
H1299	0-30 μM	Growth Inhibition Assay	72 h	IC50=1.80 μM, inhibits cell growth concentration dependently	23651443
H2052	0.01-30 μM	Growth Inhibition Assay	72 h	IC50=2.0 μM	25422081
H2170	10 μM	Function Assay	30 min	attenuates PI3K-Akt-mTOR signaling	22387988
H2170	10 μM	Function Assay	4-24 h	enhances apoptosis with erlotinib	22387988
H28	0.01-30 μM	Growth Inhibition Assay	72 h	IC50=7.2 μM	25422081
H358	1/5/10 μM	Growth Inhibition Assay	72 h	inhibits cell growth concentration dependently	25750308
H358	10 μM	Apoptosis Assay	72 h	induces apoptosis	25750308
HCT116	10 μM	Growth Inhibition Assay	24-96 h	inhibits cell growth time dependently	24686080
HCT116	10 μM	Function Assay	4 h	causes ER-stress response over the p-eIF2α branch, but does not induce CHOP	24686080
HCT116	10 μM	Apoptosis Assay	24/48 h	induces apoptosis	24686080
HDMEC	0.25/0.5/1 μM	Kinase Assay	24 h	reduces CK2 kinase activity, vWF expression and secretion	26381437
HDMEC	0.25/0.5/1 μM	Function Assay	24 h	reduces expression of VCAM-1 but not ICAM-1	26381437
HDMEC	1 μM	Function Assay	24 h	affects subcellular localization of NFATc1 and phospho-p65	26381437
HDMEC	1-50 μM	Kinase Assay	5 h	decreases CK2 kinase activity without affecting cell viability	26189586
HDMEC	50 μM	Function Assay	1/5 h	decreases the nuclear signal of phosphorylated p65 in TNF-α-stimulated HDMEC	26189586
HEK293	0.5 μM	Kinase Assay	15 min	reduces CK2 kinase activity	25887626
HEK293	3 μM	Function Assay	5 h	CK2 phosphorylates eIF3j at Ser127	25887626
Hela	0.5 μM	Kinase Assay	15 min	reduces CK2 kinase activity	25887626
HPB-ALL	1-10 μM	Growth Inhibition Assay	48 h	IC50=6.1 μM	24253024
INA-6	0-40 μM	Growth Inhibition Assay	48 h	IC50=2.42 µM	24086494
Jeko-1	0-40 μM	Growth Inhibition Assay	48 h	IC50=2.4 µM	24086494
Jurkat	1-10 μM	Growth Inhibition Assay	48 h	IC50=4.9 μM	24253024
LAMA84	0.5 μM	Kinase Assay	15 min	reduces CK2 kinase activity	25887626
LNCap	0-30 μM	Growth Inhibition Assay	4 d	IC50=4.59 μM	22832316
MDA-MB-231	2/5/10 μM	Function Assay	4 h	decreases the constitutive phosphorylation of both p-S529-p65 and p-S129-Akt	25153725
MDA-MB-231	2/5/10 μM	Function Assay	4 h	inhibits serine 529 phosphorylation and the expression of IL-6, IL-8	25153725
MOLT-4	1-10 μM	Growth Inhibition Assay	48 h	IC50=5.7 μM	24253024
MOLT-4	5 μM	Apoptosis Assay	24/48 h	induces apoptosis	24253024
Nalm6	10/20 μM	Function Assay	24 h	results in decreased PTEN phosphorylation at the CK2 target residue S380 and concomitant downregulation of PTEN protein expression	24561792
Nalm6	6/10 μM	Apoptosis Assay	48 h	induces apoptosis	24561792
NU-DUL	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Oci Ly 1	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Oci Ly 10	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Oci Ly 18	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Oci Ly 19	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Oci Ly 3	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
PC9/ER	5 µM	Function Assay	48 h	induces autophagy	25486409
PC9/GR	5 µM	Function Assay	48 h	induces autophagy	25486409
PF-382	1-10 μM	Growth Inhibition Assay	48 h	IC50=4.5 μM	24253024
platelets	1/5/10 μM	Kinase Assay	0.5 h	reduces CK2 kinase activity and platelet aggregation	26381437
Raji	5-25 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	25788269
Rec-1	0-40 μM	Growth Inhibition Assay	48 h	IC50=1.46 µM	24086494
R-LAMA84	3 μM	Function Assay	24 h	reduces CK2 activity	24012109
R-LAMA84	2.5-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	24012109
S-LAMA84	3 μM	Function Assay	24 h	reduces CK2 activity	24012109
S-LAMA84	2.5-10 μM	Growth Inhibition Assay	48 h	inhibits cell growth concentration dependently	24012109
SUP-B15	10/20 μM	Function Assay	24 h	results in decreased PTEN phosphorylation at the CK2 target residue S380 and concomitant downregulation of PTEN protein expression	24561792
SUP-B15	6/10 μM	Apoptosis Assay	48 h	induces apoptosis	24561792
U-266	0-40 μM	Growth Inhibition Assay	48 h	IC50=19.8 µM	24086494
U87-MG	1/5/10 μM	Growth Inhibition Assay	24/48/72 h	inhibits cell growth both concentration and time dependently	25241897
UM-SCC1	0.1-30 μM	Growth Inhibition Assay	1-5 d	IC50=4.1 μM	25798061
UM-SCC1	0.5/4/10 μM	Function Assay	72 h	down-regulates the expression of NF-ĸB, Bcl-XL and up-regulates the expression of p53, p21, AP-1 and IL-8 concentration dependently	25798061
UM-SCC-1	0.5-5 μM	Clonogenic Assay	14 d	inhibits clonogenic survival and sphere formation	25379016
UM-SCC46	0.1-30 μM	Growth Inhibition Assay	1-5 d	IC50=3.4 μM	25798061
UM-SCC46	0.5/4/10 μM	Function Assay	72 h	down-regulates the expression of NF-ĸB, Bcl-XL, p53, p21, AP-1 and up-regulates the expression IL-8 concentration dependently	25798061
UM-SCC-46	0.5-5 μM	Clonogenic Assay	14 d	inhibits clonogenic survival and sphere formation	25379016

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00891280	Advanced Solid Tumors ... 展开 >> Breast Cancer Inflammatory Breast Cancer Castleman's Disease Multiple Myeloma 收起 <<	Phase 1	Unknown	December 2011	United States, Arizona ... 展开 >> Mayo Clinic Arizona Recruiting Scottsdale, Arizona, United States, 85259 Contact: Clinical Trials Office Mayo Clinic Cancer Center 507-538-7623 Principal Investigator: Donald Northfelt, MD United States, Colorado Front Range Cancer Specialists Recruiting Fort Collins, Colorado, United States, 80528 Contact: P. Zeller 970-212-7609 Principal Investigator: Robert F Marschke, MD Front Range Cancer Specialists Recruiting Loveland, Colorado, United States, 80528 Contact: Pat Zeller 970-212-7609 Principal Investigator: R. McFarland, MD United States, Texas U T M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: R. Alvarez, MD ralvarez@mdanderson.org Principal Investigator: R. Alvarez, MD 收起 <<
NCT03571438	Kidney Cancer	Not Applicable	Recruiting	September 30, 2024	France ... 展开 >> Grenoble Alps Hospital Recruiting Grenoble, France, 38043 Contact: Jean-Luc Descotes, PU-PH 收起 <<
NCT02128282	Cholangiocarcinoma	Phase 1 Phase 2	Recruiting	November 2021	United States, Arizona ... 展开 >> Mayo Clinic Recruiting Scottsdale, Arizona, United States, 85259-5499 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Mitesh Borad, M.D. United States, Colorado University of Colorado- Denver Recruiting Aurora, Colorado, United States, 80045 Contact: Amy Szilard 720-848-0702 Amy.Szilard@ucdenver.edu Principal Investigator: Sarah (Lindsey) Davis, MD United States, Florida Mayo Clinic Recruiting Jacksonville, Florida, United States, 32224 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Kabir Mody, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Mayo Clinic Clinical Trials Office 855-776-0015 Principal Investigator: Joleen Hubbard, MD United States, Texas Texas Oncology - Baylor Charles A. Sammons Cancer Center Recruiting Dallas, Texas, United States, 75246 Contact: Tammy Carmical, RN 214-370-1937 tammy.carmical@usoncology.com Principal Investigator: Carlos Becerra, M.D. Texas Oncology-Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Karen Poe, RN 903-579-9869 karen.poe@usoncology.com Principal Investigator: Donald A Richards, M.D. Korea, Republic of Asan Medical Center Recruiting Seoul, Songpa-gu, Korea, Republic of, 138-736 Contact: Heung-Moon Chang, MD 82-3010-3219 ext 3210 changhm@amc.seoul.kr Contact: Seok kyung Jeong 82-2-3010-5634 jsk0213@amc.seoul.kr Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Eunyou Lee 82-2-3410-0955 ley0709@samsung.com Principal Investigator: Joon Oh Park, MD Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Myoungsun Choi 82-2-2072-7612 iamyou3@hanmail.net Principal Investigator: Do-Youn Oh, MD Severance Hospital, Yonsei University Health System Recruiting Seoul, Korea, Republic of Contact: So Young Hwang 82-2-2228-8180 syhwang@yuhs.ac Principal Investigator: Sun Young Rha, MD Taiwan China Medical University Hospital Recruiting Taichung City, Taiwan Contact: Pei-Chen Hsu +886-4-2205-2121 peggyshiu0807@gmail.com Principal Investigator: Li-Yuan Bai, M.D. 收起 <<
NCT01199718	Multiple Myeloma	Phase 1	Unknown	September 2011	United States, Ohio ... 展开 >> Recruiting Kettering, Ohio, United States, 45249 Contact: Michelle Owens, RN michelle.owens@khnetwork.org United States, Oregon Oregon Health Science University Recruiting Portland, Oregon, United States, 97239 Contact: Farnoush Abar, MD abarfa@ohsu.edu Recruiting Springfield, Oregon, United States, 97477 Contact: Jeanne Schaffer, RN jeanne.schaffer@usoncology.com United States, South Carolina Recruiting Greenville, South Carolina, United States, 29605 Contact: Jan Kueber, RN jkueber@ghs.org United States, Virginia Recruiting Norfolk, Virginia, United States, 23502 Contact: Gabrielle Geho, RN Gabrielle.Geho@usoncology.com United States, Washington Recruiting Yakima, Washington, United States, 98902 Contact: Jo Cook jo.cook@yvmh.org 收起 <<

Silmitasertib 99%+

Silmitasertib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Silmitasertib 质控信息

Silmitasertib 生物活性

Silmitasertib 细胞研究

Silmitasertib 动物研究

Silmitasertib 临床研究

Silmitasertib 参考文献

Silmitasertib 实验方案

Silmitasertib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Silmitasertib 99%+

Silmitasertib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Silmitasertib 质控信息

Silmitasertib 生物活性

Silmitasertib 细胞研究

Silmitasertib 动物研究

Silmitasertib 临床研究

Silmitasertib 参考文献

Silmitasertib 实验方案

Silmitasertib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Silmitasertib 纯度/质量文件产品仅供科研